
Vyne Therapeutics
Late stage biopharmaceutical company focused on the development and commercialization of serlopitant for the treatment of pruritus.
Market cap
$23.7m
Enterprise value
($27m)
Share price
$1.65 VYNE
Authorizing premium user...
Late stage biopharmaceutical company focused on the development and commercialization of serlopitant for the treatment of pruritus.